Clinical Trials

60 enrolled

Carcinoma, Transitional Cell

NCT04230109 2026-06-02

NeoSTAR

260 enrolled

Triple Negative Breast Neoplasms

NCT04617522 2026-06-02

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Phase 1 Recruiting

30 enrolled

Neoplasm Metastasis, Liver Failure

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

278 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06963905 2026-05-22

SIMONE

Phase 1/2 Recruiting

60 enrolled

Triple Negative Breast Neoplasms

NCT06801834 2026-05-20

EVOKE-SCLC-04

695 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07011654 2026-05-20

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

31 enrolled

Triple Negative Breast Neoplasms

NCT06431633 2026-05-18

ARIAN

129 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Recruiting

70 enrolled

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05633654 2026-04-30

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

1,514 enrolled

Triple Negative Breast Neoplasms

NCT06682728 2026-04-30

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

23 enrolled

Carcinoma, Transitional Cell

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07339059 2026-04-23

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

35 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

364 enrolled

Triple Negative Breast Neoplasms

NCT04559230 2026-03-30

Sacituzumab Govitecan in Recurrent Glioblastoma

32 enrolled

CNS

Glioblastoma

NCT05884320 2026-03-20

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Phase 1 Recruiting

20 enrolled